Drugs for Exfoliation Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 118)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Tobramycin |
Approved, Investigational |
Phase 4 |
|
32986-56-4 |
36294 5496 |
Synonyms:
11098-01-4
11111-45-8
1-Epitobramycin
32986-56-4
34337-51-4
37321-13-4
3'-Deoxykanamycin b
3'-Deoxykanamycin B
49842-07-1 (Sulfate)
54330-95-9
70322-33-7
79645-27-5
A 12253A
AB00513858
AC1L1KGY
AC1L1VI0
AC1O7GFJ
AC1Q2AOW
AKOS000715235
Aktob
BAS 00463364
BIDD:GT0503
BPBio1_000647
BRN 1357507
Brulamycin
BSPBio_000587
BSPBio_002036
C00397
C18H37N5O9
CAS-32986-56-4
CHEBI:28864
CHEBI:533587
CHEMBL1747
CID11340303
CID36294
CID5496
CID6604388
CID9804613
CID9934285
CPD000058793
D00063
DB00684
Deoxykanamycin B
Distobram
EINECS 251-322-5
Gernebcin
Gotabiotic
HMS1569N09
HMS2090B16
HMS2092M17
HSDB 3259
KBio2_001552
KBio2_004120
KBio2_006688
KBio3_001536
KBioGR_001104
KBioSS_001552
Lilly 47663
LS-146940
LS-187329
MLS000069544
MolPort-001-934-131
MolPort-003-665-548
MolPort-003-939-629
NCGC00016814-01
NCGC00178852-01
NCGC00178852-02
Nebcin
Nebcin (Sulfate)
Nebicin
Nebramycin
NEBRAMYCIN
Nebramycin 6
Nebramycin factir 6
|
Nebramycin Factir 6
Nebramycin factor 6
Nebramycin Factor 6
Nebramycin Vi
Nebramycin VI
NF 6
NSC 180514
NSC180514
O-3-amino-3-Deoxy-a-D-glucopyranosyl-(1-4)-O-(2,6-diamino-2,3,6-trideoxy-a-D-ribohexopyranosyl-(1-4))-2-deoxy-D-streptamine
O-3-amino-3-Deoxy-alpha-D-glucopyranosyl-(1-4)-O-(2,6-diamino-2,3,6-trideoxy-alpha-D-ribohexopyranosyl-(1-4))-2-deoxy-D-streptamine
O-3-Amino-3-deoxy-alpha-D-glucopyranosyl-(1-4)-O-(2,6-diamino-2,3,6-trideoxy-alpha-D-ribohexopyranosyl-(1-4))-2-deoxy-D-streptamine
O-3-amino-3-Deoxy-α-D-glucopyranosyl-(1-4)-O-(2,6-diamino-2,3,6-trideoxy-α-D-ribohexopyranosyl-(1-4))-2-deoxy-D-streptamine
Obracin
Obramycin
Prestwick_850
Prestwick0_000544
Prestwick1_000544
Prestwick2_000544
Prestwick3_000544
S2514_Selleck
SAM001246911
SMR000058793
SPBio_000295
SPBio_002508
Spectrum_001072
SPECTRUM1500579
Spectrum2_000078
Spectrum3_000588
Spectrum4_000752
Spectrum5_001038
SPRC-AB01
STK182610
Sulfate, tobramycin
Sybryx
T4014_SIGMA
Tenebrimycin
Tenemycin
TOA-(1-6)2TB-(4-1)TOC
TOA-(1-6)TOB-(4-1)TOC
Tobacin
Tobi
Tobracin
Tobracin (TN)
Tobradex
Tobradistin
Tobralex
Tobramaxin
Tobramicin
Tobramicina
Tobramicina [INN-Spanish]
Tobramitsetin
Tobramycetin
tobramycin
Tobramycin
Tobramycin (JP15/USP)
Tobramycin [USAN:BAN:INN:JAN]
Tobramycin for Inhalation
tobramycin solution for inhalation
Tobramycin solution for inhalation
Tobramycin sulfate
Tobramycin Sulfate
TOBRAMYCIN SULFATE
Tobramycin, Free Base
Tobramycine
Tobramycine [INN-French]
Tobramycinum
Tobramycinum [INN-Latin]
Tobrased
Tobrasone
Tobrex
Tobrex (TN)
TOY
UNII-VZ8RRZ51VK
|
|
2 |
|
Dexamethasone acetate |
Approved, Investigational, Vet_approved |
Phase 4 |
|
1177-87-3 |
|
Synonyms:
16alpha-Methyl-9alpha-fluoroprednisolone 21-acetate
9alpha-Fluoro-16alpha-methylprednisolone acetate
Dexamethasone 21-acetate
|
Dexamethasone acetate anhydrous
Dexamethasone acetate, anhydrous
Dexamethasoni acetas
|
|
3 |
|
Dexamethasone |
Approved, Investigational, Vet_approved |
Phase 4 |
|
50-02-2 |
5743 |
Synonyms:
(3H)-Dexamethasone
.delta.(sup 1)-9-.alpha.-Fluoro-16-.alpha.-methylcortisol
.gamma.corten
137098-19-2
16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol
16.alpha.-Methyl-9.alpha.-fluoroprednisolone
16alpha -Methyl-9alpha -fluoro-1-dehydrocortisol
16alpha -Methyl-9alpha -fluoroprednisolone
16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol
16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol
16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone
16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone
16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone
16alpha-Methyl-9alpha-fluoroprednisolone
16-alpha-Methyl-9-alpha-fluoroprednisolone
16a-Methyl-9a-fluoro-1-dehydrocortisol
16α-methyl-9α-fluoro-1-dehydrocortisol
16α-Methyl-9α-fluoro-1-dehydrocortisol
1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone
1-dehydro-16alpha -Methyl-9alpha -fluorohydrocortisone
1-dehydro-16alpha-Methyl-9alpha-fluorohydrocortisone
1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone
1-dehydro-16a-Methyl-9a-fluorohydrocortisone
1-dehydro-16α-methyl-9α-fluorohydrocortisone
1-Dehydro-16α-methyl-9α-fluorohydrocortisone
23495-06-9
31375_FLUKA
46165_FLUKA
46165_RIEDEL
50-02-2
8054-59-9
9.alpha.-Fluoro-16.alpha.-methylprednisolone
906422-84-2
9a-fluoro-16a-Methylprednisolone
9a-fluoro-16BETA-METHYLPREDNISOLONE
9A-FLUORO-16BETA-METHYLPREDNISOLONE
9alpha -fluoro-16alpha -Methylprednisolone
9alpha-fluoro-16alpha-Methylprednisolone
9alpha-fluoro-16alpha-Methyl-prednisolone
9-alpha-fluoro-16-alpha-Methylprednisolone
9alpha-Fluoro-16alpha-methylprednisolone
9-alpha-Fluoro-16-alpha-methylprednisolone
9-fluoro-11,17,21-Trihydroxy-16-methylpregna-1,4-diene-3,20-dione
9-fluoro-11alpha -Methylpregna-1,4-diene-3,20-dione
9-fluoro-16-Methylprednisolone
9α-fluoro-16α-methylprednisolone
9α-Fluoro-16α-methylprednisolone
AC-11056
AC1L1L1H
AC1Q29DM
Adexone
Aeroseb-D
Aeroseb-dex
Aeroseb-Dex
AI3-50934
Ak dex OPH otic soln 0.1%
Alcon brand OF dexamethasone
Alcon Brand of Dexamethasone
alpha -fluoro-16-alpha -Methylcortisol
Anaflogistico
Aphtasolon
Aphthasolone
apo-Dexamethasone
Auxiron
Azimycin (veterinary)
Azium
Azium (veterinary)
Azium (Veterinary)
BIDD:ER0494
BIDD:PXR0060
Bisu Ds
Bisu DS
BRD-K38775274-001-02-3
BRD-K38775274-001-06-4
BSPBio_000995
C15643
C22H29FO5
Calonat
CCRIS 7067
CHEBI:41879
CHEMBL384467
CID5743
Corson
Corsone
Cortisumman
CPD001227192
CPD-10549
D00292
D003907
D1756_SIGMA
D4902_SIGMA
D6645_SIGMA
D8893_SIGMA
D9184_SIGMA
DB01234
Decacort
Decacortin
Decaderm
Decadron
Decadron (TN)
Decadron Tablets, Elixir
Decadron, Dexamethasone
Decadron-La
Decadron-LA
Decagel
Decaject
Decaject l.a.
Decaject L.A.
Decaject-l.a.
Decaject-L.A.
Decalix
Decameth
Decasone
Decaspray
Dectancyl
Dekacort
delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol
delta1-9alpha-Fluoro-16alpha-methylcortisol
Delta1-9alpha-fluoro-16alpha-Methylcortisol
Deltafluorene
Dergramin
Deronil
Desadrene
Desametasone
Desametasone [Dcit]
Desametasone [DCIT]
Desamethasone
Desameton
Deseronil
DEX
Dexa
DEXA
Dexa mamallet
Dexa Mamallet
Dexacen-4
Dexacidin
Dexacort
Dexacortal
Dexa-cortidelt
Dexa-Cortidelt
Dexacortin
Dexa-cortisyl
Dexa-Cortisyl
Dexadeltone
Dexafarma
Dexair
Dexalona
Dexaltin
Dexa-Mamallet
Dexametasona
Dexametasona [INN-Spanish]
Dexametasone
Dexameth
Dexamethansone
dexamethasone
Dexamethasone
Dexaméthasone
Dexamethasone (JP15/USP/INN)
|
Dexamethasone [INN:BAN:JAN]
Dexamethasone acetate
Dexamethasone Acetate
Dexamethasone alcohol
Dexamethasone Alcohol
Dexamethasone base
Dexamethasone Base
Dexamethasone intensol
Dexamethasone Intensol
Dexamethasone sodium phosphate
Dexamethasone Sodium Phosphate
Dexamethasone-omega
Dexamethasonum
Dexamethasonum [INN-Latin]
Dexamethazone
Dexamonozon
Dexapolcort
Dexapos
Dexaprol
Dexa-scheroson
Dexa-Scheroson
Dexa-sine
Dexa-Sine
Dexason
Dexasone
Dexasone 0.5MG
Dexasone 0.75MG
Dexasone 4MG
Dexasporin
Dex-ide
Dex-Ide
Dexinolon
Dexinoral
Dexone
Dexone 0.5
DEXONE 0.5
Dexone 0.75
DEXONE 0.75
Dexone 1.5
DEXONE 1.5
Dexone 4
DEXONE 4
Dexonium
Dexpak
Dextelan
Dezone
Dinormon
DXM
Dxms
DXMS
ECR brand OF dexamethasone
ECR Brand of Dexamethasone
EINECS 200-003-9
Fluormethylprednisolone
Fluormone
Fluorocort
Fortecortin
Foy brand OF dexamethasone
Foy Brand of Dexamethasone
FT-0080377
Gammacorten
Hexadecadrol
Hexadrol
Hexadrol elixir
Hexadrol Elixir
Hexadrol Tablets
Hl-dex
Hl-Dex
HL-Dex
HMS1792A17
HMS1990A17
HMS2089N13
HSDB 3053
I06-1196
ICN brand OF dexamethasone
ICN Brand of Dexamethasone
IontoDex
isopto-Dex
Isopto-Dex
Lokalison F
Loverine
LS-7300
Luxazone
Maxidex
Maxidex ont 0.1%
Maxidex sus 0.1%
Maxitrol
Mediamethasone
Merck brand OF dexamethasone
Merck Brand of Dexamethasone
Merz brand 1 OF dexamethasone
Merz Brand 1 of Dexamethasone
Merz brand 2 OF dexamethasone
Merz Brand 2 of Dexamethasone
Methylfluorprednisolone
Mexidex
Millicorten
MK 125
MLS001055412
MLS001332507
MLS001332508
MolMap_000018
MolPort-003-846-433
Mymethasone
Naquasone (veterinary)
NCGC00091019-01
NCGC00091019-02
NCGC00091019-03
NCGC00091019-04
NCGC00091019-05
nchembio809-comp2
NCI60_003067
Neomycin and polymyxin b sulfates and dexamethasone
Neomycin and polymyxin b sulphates and dexamethasone
NSC 34521
NSC34521
Ocu-trol
Ocu-Trol
Oradexon
OTO-104
Pet derm III
Pet Derm Iii
Pet Derm III
Pet-Derm Iii
PHL-Dexamethasone
PMS Dexamethasone elixir 0.5mg/5ML
PMS-Dexamethasone
Policort
Posurdex
Prednisolon F
Prednisolone F
Prodex
S1322_Selleck
SAM002548948
Sandoz dexamethasone
SGCUT00126
Sk-Dexamethasone
SK-Dexamethasone
SMP1_000092
SMR000857119
SMR001227192
Spectrum5_002019
Spoloven
ST50307091
Sunia sol D
Sunia Sol D
Superprednol
TL8003317
to_000038
Tobradex
Tobramycin and dexamethasone
Tresaderm (veterinary)
Turbinaire
UNII-7S5I7G3JQL
Visumetazone
WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ G1
ZINC03875332
|
|
4 |
|
Bromfenac |
Approved |
Phase 4 |
|
91714-94-2 |
60726 |
Synonyms:
[2-amino-3-(4-bromo-Benzoyl)-phenyl]-acetate
[2-amino-3-(4-bromobenzoyl)phenyl]acetic acid
[2-amino-3-(4-bromo-Benzoyl)-phenyl]-acetic acid
[2-Amino-3-(4-bromo-benzoyl)-phenyl]-acetic acid
{2-amino-3-[(4-bromophenyl)carbonyl]phenyl}acetic acid
2-[2-amino-3-(4-bromobenzoyl)phenyl]acetic acid
2-amino-3-(4-Bromobenzoyl)benzeneacetate
2-amino-3-(4-bromobenzoyl)benzeneacetic acid
2-amino-3-(4-Bromobenzoyl)benzeneacetic acid
2-Amino-3-(4-bromobenzoyl)benzeneacetic acid
91714-94-2
AC1L1TSW
AC1Q5DQ7
AHR-10282
Ambap120638-55-3
Bromfenac
Bromfenac (INN)
Bromfenac [INN]
Bromfenac sodium
|
BROMFENAC SODIUM
Bromfenaco
Bromfenaco [Spanish]
Bromfenacum
Bromfenacum [Latin]
C15H12BrNO3
CHEBI:240107
CHEMBL1077
CID60726
D07541
DB00963
Duract
LS-178156
MolPort-000-883-091
sodium 2-amino-3-(4-bromobenzoyl) phenylacetate sesquihydrate
Sodium bromfenac
UNII-864P0921DW
Wyeth brand OF sodium bromfenac
Xibrom
|
|
5 |
|
Heparin |
Approved, Investigational |
Phase 4 |
|
9005-49-6 |
46507594 772 |
Synonyms:
101921-26-0
102785-31-9
102-94-3
104521-37-1
11078-24-3
11129-39-8
12656-11-0
37324-73-5
9041-08-1
9045-22-1
9075-96-1
913079-23-9
91449-79-5
AC1L1ROY
ALFA 87-120
ALFA 87-163
ALFA 87-198
ALFA 87-81
ALFA 88-247
Allocinnamic acid
alpha-Heparin
Alpha-Heparin
Ardeparin
Ardeparin sodium
Ariven
Arteven
Bemiparin
Bemiparin sodium
Calcilean
Calciparine
Certoparin
CID8784
cis-.beta.-Carboxystyrene
cis-Cinnamic acid
Clexane
Clivarin
Clivarine
CY 216
Cy 222
Dalteparin
Dalteparin sodium
Depo-Heparin
EINECS 232-681-7
Enoxaparin
Enoxaparin sodium
Eparina
Eparina [DCIT]
Fluxum
FR 860
Fragmin A
Fragmin B
Fragmin IV
Fraxiparin
H 2149
Hed-heparin
Hed-Heparin
Hep Flush Kit in plastic container
Hepalean
heparin
Heparin Cy 216
Heparin CY 216
Heparin Leo
Heparin Lock Flush
Heparin Lock Flush in plastic container
Heparin Lock Flush preservative free
Heparin Lock Flush preservative free in plastic container
Heparin natrium
Heparin sodium
Heparin sodium 1,000 units and sodium chloride 0.9% in plastic container
Heparin sodium 1,000 units in dextrose 5% in plastic container
Heparin sodium 1,000 units in sodium chloride 0.9% in plastic container
Heparin sodium 10,000 units in dextrose 5%
Heparin sodium 10,000 units in dextrose 5% in plastic container
Heparin sodium 10,000 units in sodium chloride 0.45%
Heparin sodium 10,000 units in sodium chloride 0.9%
Heparin sodium 12,500 units in dextrose 5%
Heparin sodium 12,500 units in dextrose 5% in plastic container
Heparin sodium 12,500 units in sodium chloride 0.45% in plastic container
Heparin sodium 12,500 units in sodium chloride 0.9%
Heparin sodium 2,000 units and sodium chloride 0.9% in plastic container
Heparin sodium 2,000 units in dextrose 5% in plastic container
Heparin sodium 2,000 units in sodium chloride 0.9% in plastic container
Heparin sodium 20,000 units and dextrose 5% in plastic container
Heparin sodium 20,000 units in dextrose 5% in plastic container
Heparin sodium 25,000 units and dextrose 5% in plastic container
Heparin sodium 25,000 units in dextrose 5%
|
Heparin sodium 25,000 units in dextrose 5% in plastic container
Heparin sodium 25,000 units in sodium chloride 0.45% in plastic container
Heparin sodium 25,000 units in sodium chloride 0.9%
Heparin sodium 25,000 units in sodium chloride 0.9% in plastic container
Heparin sodium 5,000 units and sodium chloride 0.9% in plastic container
Heparin sodium 5,000 units in dextrose 5% in plastic container
Heparin sodium 5,000 units in sodium chloride 0.45%
Heparin sodium 5,000 units in sodium chloride 0.9%
Heparin sodium 5,000 units in sodium chloride 0.9% in plastic container
Heparin sodium in plastic container
Heparin sodium preservative Free
Heparin sodium salt
Heparin sulfate
Heparin sulphate
Heparin, sodium salt
Heparina
Heparina [INN-Spanish]
Heparinate
Heparine
Heparine [INN-French]
Heparinic acid
Heparinsodiumsalt
Heparinum
Heparinum [INN-Latin]
Heparinum natricum
Hepathrom
Hepflush-10
Hep-Lock
Hep-Lock U/P
HSDB 3094
Innohep
Inno-Hep
Isocinnamic acid
Kabi 2165
KB 101
Leparan
LHN 1
Lioton 1000
Lipo-hepin
Lipo-Hepin
Liquaemin
Liquaemin Lock Flush
Liquaemin Sodium
Liquaemin sodium preservative free
Liquemin
Logiparin
Low molecular weight heparin sodium
Minolteparin sodium
MolPort-003-760-257
Multiparin
Nadroparin
Nadroparine
Novoheparin
NSC174025
Octaparin
OP 386
OP 622
Pabyrin
Panheprin
Parnaparin
Parnaparin sodium
Parvoparin
Pularin
Reviparin
Reviparin sodium
Ro 11
Sandoparin
Sodium acid heparin
Sodium heparin
Sodium heparinate
Subeparin
Sublingula
Thromboliquine
Tinzaparin
Tinzaparin sodium
Triofiban
Unfractionated heparin
UNII-12M44VTJ7B
UNII-3S182ET3UA
UNII-E47C0NF7LV
UNII-T2410KM04A
UNII-ZZ45AB24CA
Vetren
Vitrum AB
WY 90493RD
|
|
6 |
|
Timolol |
Approved |
Phase 4 |
|
26839-75-8 |
5478 33624 |
Synonyms:
(-)-3-Morpholino-4-(3-tert-butylamino-2-hydroxypropoxy)-1,2,5-thiadiazole
(2S)-1-((1,1-dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-2-propanol
(2S)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol
(2S)-1-[(1,1-dimethylethyl)amino]-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol
(S)-1-(1,1-(Dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-2-propanol
(S)-1-(tert-Butylamino)-3-((4-morpholino-1,2,5-thiadiazol-3-yl)oxy)propan-2-ol
(S)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol
(S)-timolol
131628-37-0
194288-09-0
26839-75-8
26921-17-5 (maleate (1:1) salt)
AB00513729
AC1L1PYN
AC1Q59QM
Apo-Timol
Apo-Timop
Aquanil
Betim
Betimol
Betimol (TN)
BIDD:GT0073
Blocadren
BPBio1_001008
BRD-K08806317-050-03-6
BSPBio_000916
C07141
C13H24N4O3S
CAS-26921-17-5
CHEBI:9599
CHEMBL499
CID33624
CPD001456519
D08600
DB00373
DB08625
EINECS 248-032-6
HMS2089I11
HSDB 6533
Istalol
L-714,465
Lopac0_001189
Lopac-T-6394
LS-122231
MK-950
NCGC00016038-01
NCGC00016038-02
|
NCGC00016798-01
NCGC00016798-07
NCGC00022033-02
NCGC00022033-04
NCGC00022033-05
Novo-Timol
Nu-Timolol
Oprea1_640981
Optimol
Phoxal-timolol
Prestwick0_000948
Prestwick1_000948
Prestwick2_000948
Prestwick3_000948
Proflax
S-(-)-3-(3-tert-Butylamino-2-hydroxypropoxy)-4-morpholino-1,2,5-thiadiazole
S(-)-Timolol maleate
SAM002564238
SPBio_003075
ST072193
Temserin
Tenopt
TIM
Timacar
Timacor
Tim-AK
timolol
Timolol
Timolol (INN)
Timolol (TN)
Timolol [USAN]
Timolol anhydrous
Timolol GFS
Timolol maleate
Timolol Maleate, (1:1) Salt
Timololo
Timololum
Timololum [INN-Latin]
Timopic
Timoptic
Timoptic in Ocudose
Timoptic OcuDose
Timoptic-XE
Timoptol
Tocris-0649
UNII-817W3C6175
|
|
7 |
|
Bimatoprost |
Approved, Investigational |
Phase 4 |
|
155206-00-1 |
5311027 |
Synonyms:
(5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]cyclopentyl}-N-ethylhept-5-enamide
(Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-5-heptenamide
(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]-N-ethylhept-5-enamide
155206-00-1
15M
267244-98-4
5-Heptenamide,7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ehtyl-,(5Z)
AC1NSJUW
AGN 192024
AGN-192024
Bimataprost [USAN:INN:BAN]
Bimatoprost
Bimatoprost (JAN/USAN/INN)
Bimatoprost [USAN:INN:BAN]
bimatoprostum
Bimatoprostum
|
CHEBI:39562
CHEBI:51230
CHEMBL1200963
CID5311027
D02724
DB00905
DB06863
I06-1275
I06-1277
Latisse
LS-181817
Lumigan
Lumigan (TN)
NCGC00181745-01
UNII-QXS94885MZ
ZINC04474405
|
|
8 |
|
Dorzolamide |
Approved |
Phase 4 |
|
120279-96-1 |
5284549 3154 |
Synonyms:
(4S,6S)-4-(ethylamino)-6-methyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide
(4S,6S)-4-(ethylamino)-6-methyl-7,7-dioxo-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide
(4S,6S)-4-ethylamino-6-Methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulfonate amide
(4S,6S)-4-ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulfonic acid amide
(4S,6S)-4-ethylamino-6-Methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulfonic acid amide
(4S,6S)-4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulfonic acid amide
(4S,6S)-4-ethylamino-6-Methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulphonate amide
(4S,6S)-4-ethylamino-6-Methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulphonic acid amide
(4S,trans)-4-(ethylamino)-6-methyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide
(4S,trans)-4-(ethylamino)-6-Methyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide
(4S,trans)-4-(ethylamino)-6-Methyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulphonamide 7,7-dioxide
(4S-trans)-4-(ethylamino)-5,6-dihydro-6-METHYL-4H-thieno(2,3-b)thiopyran-2-sulfonamide-7,7-dioxide
(4S-TRANS)-4-(ETHYLAMINO)-5,6-DIHYDRO-6-METHYL-4H-THIENO(2,3-B)THIOPYRAN-2-SULFONAMIDE-7,7-DIOXIDE
(4S-trans)-4-(ethylamino)-5,6-dihydro-6-METHYL-4H-thieno(2,3-b)thiopyran-2-sulphonamide-7,7-dioxide
120279-96-1
1cil
4-ethylamino-5,6-dihydro-6-Methyl-7,7-dioxide-4H-thieno(2,3-b)thiopyran-2-sulfonamide
4-ethylamino-6-Methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulfonate amide
4-ethylamino-6-Methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulfonic acid amide
4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulfonic acid amide
4-ethylamino-6-Methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulphonate amide
4-ethylamino-6-Methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulphonic acid amide
4-ethylamino-6-Methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda6-thieno[2,3-b]thiopyran-2-sulfonate amide
4-ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda6-thieno[2,3-b]thiopyran-2-sulfonic acid amide
4-ethylamino-6-Methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda6-thieno[2,3-b]thiopyran-2-sulfonic acid amide
4-ethylamino-6-Methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda6-thieno[2,3-b]thiopyran-2-sulphonate amide
4-ethylamino-6-Methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda6-thieno[2,3-b]thiopyran-2-sulphonic acid amide
4S,6S-dorzolamide
4S,6S-Dorzolamide
5,6-dihydro-4-ethylamino-6-Methyl-4H-thieno(2,3-b)thiopyran-2-sulfonamide-7,7-dioxide
AB00514687
|
AC1NR4NP
BIDD:GT0306
BPBio1_001377
BRD-K48617017-003-03-1
BSPBio_001252
C06969
CHEBI:4702
CHEMBL218490
CID5284549
D07871
DB04507
Dorzolamid
Dorzolamida
dorzolamide
Dorzolamide
Dorzolamide (DZA)
Dorzolamide (INN)
Dorzolamide chibret
Dorzolamide hydrochloride
Dorzolamide, (trans)-isomer
Dorzolamidum
HMS2089O06
MolPort-005-941-739
Prestwick0_001116
Prestwick1_001116
Prestwick2_001116
Prestwick3_001116
SPBio_003116
STK645522
Trusopt
Trusopt (TN)
|
|
9 |
|
Maleic acid |
Experimental, Investigational |
Phase 4 |
|
110-17-8, 110-16-7 |
444972 |
Synonyms:
(2E)-2-Butenedioate
(2E)-2-butenedioic acid
(2E)-2-Butenedioic acid
(2E)-But-2-enedioate
(2E)-but-2-enedioic acid
(2E)-But-2-enedioic acid
(e)-2-Butenedioate
(e)-2-Butenedioic acid
(E)-2-butenedioic acid
(E)-2-Butenedioic acid
(E)-but-2-enedioic acid
03761_FLUKA
1,2-Ethylenedicarboxylic acid, (E)
110-17-8
2-(e)-Butenedioate
2-(e)-Butenedioic acid
2-(E)-Butenedioic acid
240745_ALDRICH
240745_SIAL
26B3632D-E93F-4655-90B0-3C17855294BA
2-Butenedioic acid
2-Butenedioic acid (2E)- (9CI)
4-02-00-02202 (Beilstein Handbook Reference)
623158-97-4
AB1002616
AC1L9H76
AC1Q5T7Y
AC1Q71EM
Acidum fumaricum
AI3-24236
AKOS000118896
Allomaleate
Allomaleic acid
Allomalenic acid
ammonium fumarate
Ammonium fumarate
AR-1D9767
bmse000083
Boletate
Boletic acid
BRN 0605763
But-2-enedioic acid
Butenedioic acid
C00122
C4H4O4
Caswell No. 465E
CCRIS 1039
CHEBI:18012
CHEBI:22958
CHEMBL503160
CID444972
D02308
DB04299
e297
E-2-Butenedioic acid
EINECS 203-743-0
|
EPA Pesticide Chemical Code 051201
F0067
F8509_SIGMA
FC 33
FC 33 (acid)
FEMA No. 2488
FEMA Number 2488
fum
fumarate
Fumarate
fumarate, 10
fumaric acid
Fumaric acid (8CI)
Fumaric acid (NF)
Fumaricum acidum
Fumarsaeure
Fumarsäure
Furamag
HSDB 710
I04-1070
Kyselina fumarova
Kyselina fumarova [Czech]
Lichenate
Lichenic acid
Lichenic acid (VAN)
LMFA01170106
LS-500
Magnesium fumarate
MLS002454406
MolPort-001-780-031
MolPort-004-288-293
NCGC00091192-01
nchembio.186-comp71
nchembio.2007.47-comp1
NSC2752
NSC-2752
OR17920
S04-0167
SMR000112117
Sodium fumarate
trans-1,2-Ethylenedicarboxylate
trans-1,2-ethylenedicarboxylic acid
trans-1,2-Ethylenedicarboxylic acid
trans-2-Butenedioate
trans-2-Butenedioic acid
trans-But-2-enedioate
trans-but-2-enedioic acid
trans-But-2-enedioic acid
trans-Butenedioate
trans-Butenedioic acid
Tumaric acid
U-1149
UNII-88XHZ13131
USAF EK-P-583
W248800_ALDRICH
WLN: QV1U1VQ-T
|
|
10 |
|
Cloprostenol |
Vet_approved |
Phase 4 |
|
54276-21-0 |
|
11 |
|
Pharmaceutical Solutions |
|
Phase 4 |
|
|
|
12 |
|
Hormones |
|
Phase 4 |
|
|
|
13 |
|
Antineoplastic Agents, Hormonal |
|
Phase 4 |
|
|
|
14 |
|
glucocorticoids |
|
Phase 4 |
|
|
|
15 |
|
Hormone Antagonists |
|
Phase 4 |
|
|
|
16 |
|
Anti-Inflammatory Agents |
|
Phase 4 |
|
|
|
17 |
|
Analgesics, Non-Narcotic |
|
Phase 4 |
|
|
|
18 |
|
Analgesics |
|
Phase 4 |
|
|
|
19 |
|
Anti-Inflammatory Agents, Non-Steroidal |
|
Phase 4 |
|
|
|
20 |
|
Antirheumatic Agents |
|
Phase 4 |
|
|
|
21 |
|
Gastrointestinal Agents |
|
Phase 4 |
|
|
|
22 |
|
Anti-Infective Agents |
|
Phase 4 |
|
|
|
23 |
|
Antiemetics |
|
Phase 4 |
|
|
|
24 |
|
Adrenergic Agents |
|
Phase 4 |
|
|
|
25 |
|
calcium heparin |
|
Phase 4 |
|
|
|
26 |
|
Adrenergic beta-Antagonists |
|
Phase 4 |
|
|
|
27 |
|
Anti-Arrhythmia Agents |
|
Phase 4 |
|
|
|
28 |
|
Adrenergic Antagonists |
|
Phase 4 |
|
|
|
29 |
|
Contraceptive Agents |
|
Phase 4 |
|
|
|
30 |
|
Dipivefrin |
Approved |
Phase 3 |
|
52365-63-6 |
3105 |
Synonyms:
( -)-2,2-Dimethylpropansaeure-4-(1-hydroxy-2-(methylamino)ethyl)-1,2-phenylenester
( -)-4-(1-Hydroxy-2-methylaminoethyl)-o-phenylendipivalat
(+-)-3,4-Dihydroxy-alpha-((methylamino)methyl)benzyl alcohol 3,4-dipivalate
(+-)-4-[1-hydroxy-2-(methylamino)ethyl]-o-phenylene divavalate
(+-)-4-[1-Hydroxy-2-(methylamino)ethyl]-O-phenylene divavalate
(+-)-4-[1-Hydroxy-2-(methylamino)ethyl]-O-phenylene divavalic acid
(±)-4-[1-hydroxy-2-(methylamino)ethyl]-o-phenylene divavalate
(RS)-4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-phenylen dipivalat
[2-(2,2-dimethylpropanoyloxy)-4-[1-hydroxy-2-(methylamino)ethyl]phenyl] 2,2-dimethylpropanoate
1-(3',4'-dipivaloyloxyphenyl)-2-methylamino-1-ethanol
1-(3',4'-Dipivaloyloxyphenyl)-2-methylamino-1-ethanol
2,2-Dimethylpropanoic acid 4-[1-hydroxy-2-(methylamino)ethyl]-1,2-phenylene ester
4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-phenylen dipivalat
4-[1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diyl bis(2,2-dimethylpropanoate)
4-[1-hydroxy-2-(methylamino)ethyl]-o-phenylene divavalate
4-[1-Hydroxy-2-(methylamino)ethyl]-O-phenylene divavalate
4-[1-Hydroxy-2-(methylamino)ethyl]-O-phenylene divavalic acid
52365-63-6
AB00514686
AC1L1F6K
Adrenaline dipivalate
AKOS003662293
AKPro
Alcon brand OF dipivefrin hydrochloride
Allergan brand OF dipivefrin hydrochloride
apo-Dipivefrin
Apotex brand OF dipivefrin hydrochloride
BPBio1_000688
BRD-A47494775-003-03-0
BSPBio_000624
C06963
C19H29NO5
CHEBI:4646
CID3105
D Epifrin
D02349
DB00449
Diopine
Dipivaloylepinephrine
dipivalyl epinephrine
Dipivalyl epinephrine
dipivefrin
Dipivefrin
Dipivefrin (USAN)
|
Dipivefrin [USAN]
Dipivefrin acetate, (+-)-isomer
Dipivefrin citrate (1:1), (+-)-isomer
Dipivefrin HCL
Dipivefrin hydrochloride
Dipivefrin hydrochloride, (+-)-isomer
Dipivefrin monophosphate, (+-)-isomer
Dipivefrin monosulfate, (+-)-isomer
Dipivefrin nitrate, (+-)-isomer
Dipivefrin perchlorate
Dipivefrin propanoate, (+-)-isomer
Dipivefrin tartrate (1:1), (+-)-(R-(r*,r*))-isomer
Dipivefrin tartrate (1:1), (R)-(R-(r*,r*))-isomer
Dipivefrin, (R)-isomer
Dipivefrina
Dipivefrina [INN-Spanish]
Dipivefrine
Dipivéfrine
Dipivefrine (INN)
Dipivefrinum
Dipivefrinum [INN-Latin]
Dipoquin
Glaucothil
Glaudrops
Ioquin brand OF dipivefrin hydrochloride
K 30081
L000915
LS-121419
NCGC00179499-01
nchembio747-comp3
Ophtho-Dipivefrin
Pharm-allergan brand OF dipivefrin hydrochloride
Pharmascience brand OF dipivefrin hydrochloride
PMS-Dipivefrin
Prestwick0_000632
Prestwick1_000632
Prestwick2_000632
Prestwick3_000632
Propine
Propine C Cap B.I.D.
ratio-Dipivefrin
Ratiopharm brand OF dipivefrin hydrochloride
SPBio_002843
UNII-8Q1PVL543G
|
|
31 |
|
Apraclonidine |
Approved |
Phase 3 |
|
66711-21-5 |
2216 |
Synonyms:
2-(4-amino-2,6-dichloro)phenyliminoimidazolidine
2-(4-amino-2,6-dichloro)Phenyliminoimidazolidine
2-(4-Amino-2,6-dichloroanilino)-2-imidazoline hydrochloride
2,6-dichloro-1-N-(4,5-dihydro-1H-imidazol-2-yl)benzene-1,4-diamine
2,6-dichloro-N(1)-(4,5-dihydro-1H-imidazol-2-yl)benzene-1,4-diamine
4-Aminoclonidine
66711-21-5
A0779_SIGMA
AC-12697
AC1L1D6L
ALO 2145
Aplonidine
Apraclonidina
Apraclonidina [INN-Spanish]
apraclonidine
Apraclonidine
Apraclonidine (INN)
Apraclonidine [INN:BAN]
Apraclonidine hydrochloride
Apraclonidinum
Apraclonidinum [INN-Latin]
C07668
C9H10Cl2N4
CHEBI:127495
CHEBI:2788
CHEMBL647
|
CID2216
D07461
DB00964
Iopidine
Iopidine (TN)
Iopidine Eye
Iopimax
L000686
L013394
Lopac0_000033
Lopac-A-0779
LS-176536
MolPort-003-940-020
MolPort-005-933-986
NCGC00015033-01
NCGC00015033-03
NCGC00162050-01
p-aminoclonidine
P-Aminoclonidine
para-aminoclonidine
Para-aminoclonidine
PDSP1_000790
PDSP2_000778
SMP1_000016
UNII-843CEN85DI
ZINC00020231
|
|
32 |
|
Travoprost |
Approved |
Phase 3 |
|
157283-68-6 |
5282226 |
Synonyms:
(((1R)-(1alpha(Z),2beta(1E,3R*),3alpha,5alpha))-7-(3,5-dihydroxy-2-(3-hydroxy-4-(3-trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-5-heptenoic acid, 1-methylethyl ester
(+)-Fluprostenol isopropyl ester
(1R-(1alpha(Z),2beta(1E,3R*),3alpha,5alpha))-7-(3,5-Dihydroxy-2-(3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-5-heptenoic acid, 1-methylethyl ester
(Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((1E,3R)-3-hydroxy-4-((alpha,alpha,alpha-trifluoro-m-isopropyl-tolyl)oxy)-1-butenyl)cyclopentyl)-5-heptenoate
157283-68-6
5-Heptenoic acid,7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3R)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-,1-methylethyl ester,(5Z)
AC1NQZOS
AC-6103
AL6221
AL-6221
C26H35F3O6
CHEBI:746859
CHEMBL1200799
CID5282226
D01964
DB00287
Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(a,a,a-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate
Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(a,a,a-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoic acid
isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(alpha,alpha,alpha-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate
Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(alpha,alpha,alpha-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate
|
Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(alpha,alpha,alpha-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoic acid
isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(α,α,α-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate
Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(α,α,α-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate
Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(α,α,α-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoic acid
LS-173521
propan-2-yl (5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-en-1-yl}cyclopentyl]hept-5-enoate
propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]cyclopentyl]hept-5-enoate
S1554_Selleck
Travatan
Travatan (TN)
Travatan Alcon
Travatan Z
Travatan, Travoprost
Travatanz
Travoprost
Travoprost (JAN/USAN/INN)
Travoprost [USAN]
Travoprostum
Z, Travatan
ZINC04474682
|
|
33 |
|
Triamcinolone |
Approved, Vet_approved |
Phase 2, Phase 3 |
|
124-94-7 |
31307 |
Synonyms:
(8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
11.Beta.,16.alpha.,17.alpha., 21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione
11.beta.,16.alpha.,17.alpha.,21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione
11b,16a,17a,21-Tetrahydroxy-9a-fluoro-1,4-pregnadiene-3,20-dione
11beta,16alpha,17alpha,21-Tetrahydroxy-9alpha-fluoro-1,4-pregnadiene-3,20-dione
11-beta,16-alpha,17-alpha,21-Tetrahydroxy-9-alpha-fluoro-1,4-pregnadiene-3,20-dione
11β,16α,17α,21-tetrahydroxy-9α-fluoro-1,4-pregnadiene-3,20-dione
124-94-7
4-08-00-03629 (Beilstein Handbook Reference)
83474-03-7
9.Alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahy
9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione
9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9.Alpha.-Fluoro-11.beta.,16.alpha.,17.alpha., 21-tetrahydroxypregna-1,4-diene-3,20-d
9.alpha.-Fluoro-11.beta.,16.alpha.,17.alpha.,21-tetrahydroxypregna-1,4-diene-3,20-dione
9.alpha.-Fluoro-16.alpha.-hydroxyprednisolone
9a-fluoro-11b,16a,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione
9a-fluoro-11b,16a,17a,21-Tetrahydroxypregna-1,4-diene-3,20-dione
9a-fluoro-16a-Hydroxyprednisolone
9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione
9alpha-fluoro-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione
9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-alpha-Fluoro-11-beta,16-alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9alpha-fluoro-11beta,16alpha,17alpha,21-Tetrahydroxypregna-1,4-diene-3,20-dione
9alpha-fluoro-16alpha-Hydroxyprednisolone
9alpha-Fluoro-16alpha-hydroxyprednisolone
9-alpha-Fluoro-16-alpha-hydroxyprednisolone
9-Fluoro-11,16,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-fluoro-11b,16a,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione
9-fluoro-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione
9-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9α-fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9α-fluoro-11β,16α,17α,21-tetrahydroxypregna-1,4-diene-3,20-dione
9α-fluoro-16α-hydroxyprednisolone
AC1L1LDH
AC1Q5HJC
AC-2072
Adcortyl
Aristocort
Aristocort A
Aristocort Tablets
Aristogel
Aristospan
Azmacort
Bio-0662
BPBio1_000154
BRD-K77554836-001-03-3
BRN 2341955
BSPBio_000140
C21H27FO6
Celeste
CHEMBL1451
CID31307
Cinolone
Cinolone-T
CL 19823
D00385
D014221
DB00620
Delphicort
droxypregna-1,4-diene-3,20-dione
EINECS 204-718-7
EU-0101179
Fluoxiprednisolone
Fluoxyprednisolone
Flutex
Fougera
HMS1568G22
HMS2090D12
HSDB 3194
ione
Kenacort
Kenacort (TN)
Kenacort-A
Kenacort-Ag
Kenacort-AG
Kenalog
Kenalog in Orabase
|
Kenalog-10
Kenalog-40
Kenalog-H
Ledercort
Lopac0_001179
LS-698
MLS000028542
MLS001066543
MLS002695935
MolPort-002-528-981
Mycolog
Nasacort
Nasacort Aq
Nasacort Hfa
NCGC00021580-03
NCGC00021580-04
NCGC00021580-05
NCGC00021580-06
NCGC00021580-07
nchembio.2007.53-comp7
NCI60_000750
NSC 13397
NSC13397
Omcilon
Omicilon
Oracort
Oralone
Orion
Polcortolon
Pregna-1,4-diene-3,20-dio
Pregna-1,4-diene-3,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-, (11beta,16alpha)
Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,16alpha,17,21-tetrahydroxy- (8CI)
Prestwick_438
Prestwick0_000120
Prestwick1_000120
Prestwick2_000120
Prestwick3_000120
Rodinolone
S1933_Selleck
Sk-Triamcinolone
SK-Triamcinolone
SMP1_000300
SMR000058333
SPBio_002079
T6376_SIGMA
Tiamcinolonum
Tiamcinolonum [INN-Latin]
Triacet
Triacort
Triamcet
Triamcinalone
Triamcinlon
Triamcinolon
Triamcinolona
Triamcinolona [INN-Spanish]
triamcinolone
Triamcinolone
Triamcinolone (JP15/USP/INN)
TRIAMCINOLONE (SEE ALSO TRIAMCINOLONE ACETONIDE (76-25-5) AND TRIAMCINOLONE DIACETATE (67-78-7))
Triamcinolone [USAN:INN:BAN:JAN]
Triamcinolone acetonide
Triamcinolone diacetate
Triamcinolone hexacetonide
Triamcinolonum
Triamcinolonum [INN]
Triam-Tablinen
Triatex
Tricortale
Triderm
Trilone
Tri-Nasal
Tristoject
Trymex
UNII-1ZK20VI6TY
Vetalog
Volon
Volon A
WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ GQ
ZINC03882036
|
|
34 |
|
Bevacizumab |
Approved, Investigational |
Phase 2, Phase 3 |
|
216974-75-3 |
|
Synonyms:
216974-75-3
antiVEGF
Anti-VEGF Humanized Monoclonal Antibody
anti-VEGF monoclonal antibody
Anti-VEGF monoclonal antibody
Avastin
Avastin (TN)
bevacizumab
|
Bevacizumab
Bevacizumab (genetical recombination)
Bevacizumab (genetical recombination) (JAN)
bevacizumab-awwb
D06409
R-435
rhuMAb-VEGF
|
|
35 |
|
Proxymetacaine |
|
Phase 3 |
|
|
|
36 |
|
Brimonidine Tartrate |
|
Phase 3 |
|
70359-46-5 |
|
37 |
|
Lubricant Eye Drops |
|
Phase 3 |
|
|
|
38 |
|
Immunologic Factors |
|
Phase 2, Phase 3 |
|
|
|
39 |
|
triamcinolone acetonide |
|
Phase 2, Phase 3 |
|
|
|
40 |
|
Triamcinolone diacetate |
|
Phase 2, Phase 3 |
|
|
|
41 |
|
Immunosuppressive Agents |
|
Phase 2, Phase 3 |
|
|
|
42 |
|
Triamcinolone hexacetonide |
|
Phase 2, Phase 3 |
|
|
|
43 |
|
Antimetabolites |
|
Phase 2, Phase 3 |
|
|
|
44 |
|
Endothelial Growth Factors |
|
Phase 2, Phase 3 |
|
|
|
45 |
|
Mitogens |
|
Phase 2, Phase 3 |
|
|
|
46 |
|
Gentamicins |
|
Phase 2, Phase 3 |
|
|
|
47 |
|
Angiogenesis Inhibitors |
|
Phase 2, Phase 3 |
|
|
|
48 |
|
Antineoplastic Agents, Immunological |
|
Phase 2, Phase 3 |
|
|
|
49 |
|
rituximab |
Approved |
Phase 2 |
|
174722-31-7 |
10201696 |
Synonyms:
AntiCD20
IDEC-102
IDEC-C2B8
Ig gamma-1 chain C region
Mabthera
|
MabThera
Rituxan
rituximab
rituximab-abbs
rituximab-pvvr
|
|
50 |
|
Gemcitabine |
Approved |
Phase 2 |
|
95058-81-4 |
60750 |
Synonyms:
103882-84-4
122111-03-9
2',2'-DFDC
2',2'-DiF-dC
2',2'-difluoro-2'-Deoxycytidine
2',2'-Difluoro-2'-deoxycytidine
2',2'-Difluorodeoxycytidine
2'-Deoxy-.beta.-D-2',2'-difluorocytidine
2'-Deoxy-2',2'-difluorocytidine
2'-Deoxy-2',2''-difluorocytidine-5'-O-monophosphate
2'-Deoxy-2'-difluorocytidine
4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
4-amino-1-((2R,4R,5R)-3,3-difluoro-4-Hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
4-Amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
4-Amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl]-1H-pyrimidin-2-one
95058-81-4
AB1004842
AC1L1TUQ
C07650
CCRIS 8984
CHEBI:175901
CHEMBL888
CID60750
Cytidine, 2'-deoxy-2',2'-difluoro-2'-Deoxy-.beta.-D-2',2'-difluorocytidine
D02368
DB00441
DDFC
DFdC
DFDC
DFdCyd
Folfugem
Gamcitabine
Gemcel
Gemcin
Gemcitabin
|
Gemcitabina
Gemcitabina [INN-Spanish]
gemcitabine
Gemcitabine
Gemcitabine (USAN/INN)
Gemcitabine HCl
Gemcitabine hydrochloride
Gemcitabine stereoisomer
Gemcitabine, (alpha-D-threo-pentofuranosyl)-isomer
Gemcitabine, (beta-D-threo-pentafuranosyl)-isomer
Gemcitabine, (D-threo-pentafuranosyl)-isomer
Gemcitabinum
Gemcitabinum [INN-Latin]
GemLip
Gemtro
Gemzar
Gemzar (hydrochloride)
GEO
HMS2089P10
HSDB 7567
Inno-D07001
LS-59139
LY 188011
LY188011
LY-188011
NCGC00168784-01
NChemBio.2007.10-comp25
nchembio.573-comp7
nchembio.90-comp2
NSC 613327
NSC613327
TL8005979
UNII-B76N6SBZ8R
Zefei
ZINC18279854
|
|
Interventional clinical trials:
(show top 50)
(show all 71)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
The Reggio Emilia Study on Bromfenac for Patients With PseudoEXfoliation Syndrome Undergoing Cataract Surgery: the REPEX Study |
Completed |
NCT02137161 |
Phase 4 |
Dexamethasone+Tobramycin eye drop;Bromfenac eye drop |
2 |
Aqueous Flare of a Hydrophobic Acrylic Single-piece Open-loop IOL With Modified Material Surface Properties |
Completed |
NCT01767012 |
Phase 4 |
|
3 |
Efficacy Of The Bimatoprost/Timolol Fixed Combination In Patients Treated With Bimatoprost for Primary Open Angle Glaucoma, Exfoliation Glaucoma or Ocular Hypertension. |
Completed |
NCT00941096 |
Phase 4 |
Bimatoprost and Bimatoprost/Timolol fixed combination. |
4 |
Assessing Cosopt Switch Patients |
Completed |
NCT00273442 |
Phase 4 |
timolol maleate;dorzolamide/timolol maleate fixed combination |
5 |
24-Hour Intraocular Pressure Control Obtained With the Bimatoprost/Timolol Fixed Combination Compared With Latanoprost as First Choice Therapy in Subjects With Exfoliation Syndrome, or Exfoliative Glaucoma |
Completed |
NCT01448837 |
Phase 4 |
Bimatoprost/Timolol, 24-hour intraocular pressure monitoring;Latanoprost, 24-hour intraocular pressure monitoring |
6 |
Randomized Multicentre Prospective Study of Selective Laser Trabeculoplasty (SLT) vs. Argon Trabeculoplasty (ALT) in Patients With Pseudoexfoliation Glaucoma and Ocular Hypertension |
Completed |
NCT01126203 |
Phase 3 |
|
7 |
The Effect of Intracameral Triesence (Triamcinolone Acetonide Injectable Suspension) on Ocular Inflammation After Trabeculectomy, Tube Shunt Implantation or Combined Trabeculectomy With Cataract Surgery |
Completed |
NCT00853905 |
Phase 2, Phase 3 |
Triesence;balanced salt solution BSS |
8 |
24-Hour Intraocular Pressure (IOP) Control With Travoprost/Timolol Fixed Combination |
Completed |
NCT00331240 |
Phase 3 |
travoprost/timolol fixed combination;placebo (artificial tears) |
9 |
Bevacizumab Versus Mitomycin C as Trabeculectomy Adjuvant in Uncontrolled Glaucoma: A Randomized Pilot Trial. |
Completed |
NCT02901236 |
Phase 2, Phase 3 |
Mitomycin C;Bevacizumab |
10 |
A Study to Assess the Safety, Efficacy and Tolerability of Rituximab (Mabthera) in Combination With Plasma Exchange (PEX) in Patients With Acute Thrombotic Thrombocytopenic Purpura (TTP) |
Unknown status |
NCT00937131 |
Phase 2 |
Rituximab |
11 |
A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma |
Completed |
NCT01936389 |
Phase 2 |
AR-12286 |
12 |
Randomized Phase II-III Trial of Peri- or Post-Operative Chemotherapy in Resectable Pancreatic Adenocarcinoma |
Completed |
NCT01150630 |
Phase 2 |
capecitabine;cisplatin;epirubicin;gemcitabine |
13 |
PEXG (Cisplatin, Epirubicin, Capecitabine, Gemcitabine) Versus PDXG (Cisplatin, Docetaxel, Capecitabine, Gemcitabine) in Locally Advanced or Metastatic Pancreatic Adenocarcinoma: A Randomized Phase II Trial |
Completed |
NCT00966706 |
Phase 2 |
capecitabine;cisplatin;docetaxel;epirubicin hydrochloride;gemcitabine hydrochloride |
14 |
Phacotrabeculectomy With Collagen Matrix Implant (Ologen®) Versus Mitomycin C Augmented Phacotrabeculectomy: Clinical Results of a Prospective Randomized Trial |
Completed |
NCT03506542 |
Phase 2 |
Mitomycin C |
15 |
A Pilot Study of Neoadjuvant and Adjuvant mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma |
Completed |
NCT01660711 |
Phase 2 |
5 Fluorouracil;Leucovorin;Irinotecan;Oxaliplatin |
16 |
Evaluation of LOXL1 Polymorphism in Pseudoexfoliation Syndrome in the Korean Population |
Unknown status |
NCT01515735 |
|
|
17 |
Monitoring of the Intraocular Pressure After Selective Laser Trabeculoplasty Using iCare Home |
Unknown status |
NCT03310788 |
|
|
18 |
Comparison of the Capsular Stability With Two Different IOL Models in Patients With Pseudoexfoliation Syndrome: an Exploratory Study |
Unknown status |
NCT02155478 |
|
|
19 |
Prospective Study to Examine the Efficacy of a Capsular Tension Ring (CTR) in Preventing Anterior Capsule Shrinkage After Cataract Surgery in Exfoliation Syndrome (XFS) With no Zonular Weakness |
Unknown status |
NCT01455168 |
|
|
20 |
Measurement of Ocular Tensional Fluctuation by Triggerfish Lens Before and After Cataract Surgery in Patients With Exfoliative Glaucoma |
Unknown status |
NCT02658071 |
|
|
21 |
Glaucoma Including Pseudoexfoliation Syndrome (SFB 539) |
Unknown status |
NCT00947869 |
|
|
22 |
The International Collaborative Exfoliation Syndrome Treatment Study |
Unknown status |
NCT00804115 |
|
Latanoprost with Pilocarpine vs Timolol or Cosopt |
23 |
Methods to Manage Intra-operative Floppy-iris Syndrome and Poor Pupil Dilation in Cataract Surgery: an Exploratory Study |
Unknown status |
NCT01778959 |
|
|
24 |
Comparison of Efficacy of Prostaglandin Analogues (Xalatan) and Aqueous Suppressants (Cosopt) in Reducing Intraocular Pressure Following Selective Laser Trabeculoplasty in the Management of Open-Angle Glaucoma. |
Unknown status |
NCT00440336 |
|
Cosopt;Xalatan |
25 |
Following Patients After Selective and Pascal Laser Trabeculoplasty for Treatment of Chronic Open-Angle Glaucoma |
Unknown status |
NCT02679482 |
|
|
26 |
Corneal Endothelial Cell Loss After Trabeculectomy Versus Combined Trabeculectomy Phakoemulsification and IOL Implantation |
Unknown status |
NCT03107000 |
|
|
27 |
Study of the Efficacy of a Single Session Micropulse Laser Trabeculoplasty as an Adjunctive Measure in Decreasing Intraocular Pressure in Patients Suffering From Pseudoexfoliation Glaucoma |
Completed |
NCT03483402 |
|
|
28 |
Pseudoexfoliation Syndrome in Myopes Defined With Optical Low Coherence Reflectometry |
Completed |
NCT01637740 |
|
|
29 |
Assessment of Long-term Intraocular Lens (IOL) Decentration and Tilt in Eyes With Pseudoexfoliation Syndrome (PES) Following Cataract Surgery |
Completed |
NCT03453827 |
|
|
30 |
Plasma Levels of Matrix Metalloproteinases and Degree of DNA Fragmentation in Patients With Pseudoexfoliation Syndrome and Open-Angle Glaucoma (PEXG) |
Completed |
NCT00327613 |
|
|
31 |
Changes in Ocular Rigidity After Trabeculectomy in Patients With POAG or PEX |
Completed |
NCT02544646 |
|
|
32 |
Anti-inflammatory Therapy Following Selective Laser Trabeculoplasty (SLT): A Randomized, Masked, Placebo Controlled Study |
Completed |
NCT00485108 |
|
prednisolone 1%;ketorolac 0.5%;Artificial Tears (Methyl cellulose drops) |
33 |
A Comparison of the Additivity of Brinzolamide Ophthalmic Suspension, 1% (Azopt) and Brimonidine Tartrate Ophthalmic Solution, 0.15% (Alphagan P) to Travoprost Ophthalmic Solution, 0.004% (Travatan) in Patients With Elevated IOP on Travoprost. A Three Month Double-Masked, Multi-Center Trial in the United States |
Completed |
NCT00121147 |
|
Travatan;Azopt;Alphagan P |
34 |
Optical Low Coherence Reflectometry Enables Preoperative Detection of Zonular Weakness in Pseudoexfoliation Syndrome |
Completed |
NCT01298895 |
|
|
35 |
Evaluation of Scanning Laser Polarimetry Findings in Individuals With Exfoliation Syndrome Compared With Normal Controls |
Completed |
NCT01022281 |
|
|
36 |
A Prospective, Multicenter Clinical Trial Designed to Evaluate the Safety and Performance of the AqueSys XEN 45 Glaucoma Implant in Subjects With Refractory Glaucoma |
Completed |
NCT02036541 |
|
|
37 |
Central Corneal Thickness in Patients With Exfoliation Syndrome, Exfoliative Glaucoma, Exfoliative Glaucoma, Primary Open-angle Glaucoma and Ocular Hypertension |
Completed |
NCT01023997 |
|
|
38 |
Messenger Ribonucleic Acid Expression in Lymphocytes of Glaucoma Patients |
Completed |
NCT00327509 |
|
|
39 |
The Efficacy of Citicoline in Eyedrops (OMK1) in Reducing the Progression of Glaucoma |
Completed |
NCT04020705 |
|
|
40 |
Clinical Factors Associated With Floppy Iris Signs: a Prospective Study From Two Centers |
Completed |
NCT00472888 |
|
|
41 |
A 3-month, Observational Study Investigating With Electronic Monitoring the Level of Adherence and Treatment Satisfaction With Latanoprost/Timolol Fixed Combination Versus Unfixed Therapy in Open-angle Glaucoma |
Completed |
NCT01281020 |
|
|
42 |
Outcomes of Cataract Surgeries in Patients With Advanced Age |
Completed |
NCT04140383 |
|
|
43 |
The Diurnal and Nocturnal Effect of Simbrinza and Timolol on Intraocular Pressure and Ocular Perfusion Pressure |
Completed |
NCT02165631 |
|
|
44 |
The Effect of Hydrodynamic Parameters on Corneal Endothelial Cell Loss After Phacoemulsification |
Completed |
NCT00370955 |
|
|
45 |
Late Dislocation and Haptic Deformation of a Hydrophilic Intraocular Lens: Characteristics, Incidence Rates and Predisposing Factors |
Completed |
NCT02747667 |
|
|
46 |
Evaluation of Choroidal Thickness Using Spectral Optical Coherence Tomography in Pseudoexfoliation Glaucoma and Primary Open Angle Glaucoma |
Completed |
NCT03373942 |
|
|
47 |
Analysis of Killer Immunoglobulin-like Receptor Transcripts Expression for the Diagnosis of Epidermotropic Cutaneous T-cell Lymphomas (Mycosis Fungoid and Sézary Syndrome) in Patients With Erythroderma or Erythematous Patches/Plaques. |
Completed |
NCT00748319 |
|
|
48 |
Diagnostic Imaging for Intraoperative Floppy Iris Syndrome |
Completed |
NCT01252472 |
|
|
49 |
Investigating the Genetic Basis of Pseudoexfoliation Syndrome and Angle-closure Glaucoma |
Recruiting |
NCT03423758 |
|
|
50 |
IOP Monitoring After Trabeculectomy Using iCare Home |
Recruiting |
NCT03445806 |
|
|
|